**Nanoglio:**
Nanotechnology based immunotherapy for glioblastoma

**Coordinator:** Angela Santoni, IRCCS Neuromed, Pozzilli, Italy, angela.santoni@uniroma1.it

**Partners:** Bozena Kaminska, Neurobiology Center Nencki Institute of Experimental Biology, Warsaw Poland | Ling Peng, Centre Nationale de Recherche Scientifique (CNRS), Marseille France | Mafalda Videira, University of Lisbon, Lisbon, Portugal | Costas Demetzos, University of Athens, Athens, Greece | Sabrina Pricl, University of Trieste, Trieste, Italy | Patrick March, Institut National de la Santé et de la Recherche Médicale (INSERM), La Tronche France.

Glioblastoma (GBM) is a devastating brain tumor, with no efficacious therapeutic treatment. Among the factors contributing to tumor aggressiveness is a reduced immunological reaction against cancer cells. This project aims at inducing a specific antitumor response by delivering immunomodulatory agents to the tumor lesions, to re-educate the different components of the immune system to acquire an antitumor phenotype. Different nanosystems (nDDSs) constructed with lipids, polymers and dendrimers will be used to transport immunomodulators across the defective blood brain barrier, into the tumor lesions, and assess the anticancer activity using rodent models. The expectation is to identify promising anti-GBM candidates for future therapeutic implementation.

"inducing a specific antitumor response by delivering immunomodulatory agents"